Facts You Need to Understand AbbVie Stock

By Kim Brooks • Wednesday, March 26 15:09 • Permanent Link

Large-cap Health Care company AbbVie has moved -0.0% so far today on a volume of 3,835,243, compared to its average of 6,181,867. In contrast, the S&P 500 index moved -1.0%.

AbbVie trades -4.92% away from its average analyst target price of $211.73 per share. The 25 analysts following the stock have set target prices ranging from $173.0 to $250.0, and on average have given AbbVie a rating of buy.

If you are considering an investment in ABBV, you'll want to know the following:

AbbVie's current price is 964.6% above its Graham number of $18.91, which implies that at its current valuation it does not offer a margin of safety
AbbVie has moved 11.6% over the last year, and the S&P 500 logged a change of 10.1%
Based on its trailing earnings per share of 2.4, AbbVie has a trailing 12 month Price to Earnings (P/E) ratio of 83.9 while the S&P 500 average is 29.3
ABBV has a forward P/E ratio of 16.6 based on its forward 12 month price to earnings (EPS) of $12.13 per share
Its Price to Book (P/B) ratio is 106.85 compared to its sector average of 3.53
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide.
Based in North Chicago, the company has 55,000 full time employees and a market cap of $356.11 Billion. AbbVie currently returns an annual dividend yield of 3.1%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.